News + Filings Transactions
All All (ex-4s) 10-K 10-Q 8-K 3,4,5 Proxy Prospectus Other
|
BIENAIME JEAN JACQUES
|
Create: Alert |
All | News | Filings
Date Filed | Type | Description |
08/09/2023 |
4
| BIENAIME JEAN JACQUES (CEO) has filed a Form 4 on BIOMARIN PHARMACEUTICAL INC
Txns:
| Sold 4,000 shares
@ $88.1, valued at
$352.4k
Sold 6,000 shares
@ $88.29, valued at
$529.7k
|
|
08/08/2023 |
144
| Form 144 - Report of proposed sale of securities: |
08/07/2023 |
144
| Form 144 - Report of proposed sale of securities: |
06/16/2023 |
4
| BIENAIME JEAN JACQUES (Director) has filed a Form 4 on INCYTE CORP
Txns:
| Granted 2,505 shares
@ $0 Granted 11,294 options to buy
@ $61.44, valued at
$693.9k
|
|
05/16/2023 |
4
| BIENAIME JEAN JACQUES (CEO) has filed a Form 4 on BIOMARIN PHARMACEUTICAL INC
Txns:
| Paid exercise price by delivering 6,337 shares
@ $93.93, valued at
$595.2k
Paid exercise price by delivering 33,644 shares
@ $93.93, valued at
$3.2M
Exercised 39,130 options to buy
@ $67.81, valued at
$2.7M
Exercised 7,370 options to buy
@ $67.81, valued at
$499.8k
|
|
05/15/2023 |
4
| BIENAIME JEAN JACQUES (CEO) has filed a Form 4 on BIOMARIN PHARMACEUTICAL INC
Txns:
| Sold 24,439 shares
@ $94.55, valued at
$2.3M
Sold 5,561 shares
@ $95.22, valued at
$529.5k
Exercised 30,000 options to buy
@ $67.81, valued at
$2M
|
|
05/11/2023 |
4
| BIENAIME JEAN JACQUES (CEO) has filed a Form 4 on BIOMARIN PHARMACEUTICAL INC
Txns:
| Granted 317 shares
@ $66.88, valued at
$21.2k
Sold 13,626 shares
@ $94.22, valued at
$1.3M
Sold 14,964 shares
@ $95.49, valued at
$1.4M
Sold 1,410 shares
@ $95.9, valued at
$135.2k
Exercised 30,000 shares
@ $67.81, valued at
$2M
Sold 21,453 shares
@ $94.65, valued at
$2M
Sold 8,547 shares
@ $95.34, valued at
$814.9k
Exercised 30,000 options to buy
@ $67.81, valued at
$2M
|
|
05/11/2023 |
144
| Form 144 - Report of proposed sale of securities: |
05/10/2023 |
144
| Form 144 - Report of proposed sale of securities: |
05/09/2023 |
144
| Form 144 - Report of proposed sale of securities: |
04/06/2023 |
144
| Form 144 - Report of proposed sale of securities: |
03/17/2023 |
4
| BIENAIME JEAN JACQUES (CEO) has filed a Form 4 on BIOMARIN PHARMACEUTICAL INC
Txns:
| Granted 36,100 shares
@ $0 Paid exercise price by delivering 9,437 shares
@ $87.74, valued at
$828k
Paid exercise price by delivering 88,623 shares
@ $93.41, valued at
$8.3M
Granted 49,430 options to buy
@ $87.74, valued at
$4.3M
|
|
03/14/2023 |
4
| BIENAIME JEAN JACQUES (CEO) has filed a Form 4 on BIOMARIN PHARMACEUTICAL INC
Txns:
| Sold 15,000 shares
@ $92.28, valued at
$1.4M
Sold 8,000 shares
@ $90.45, valued at
$723.6k
Exercised 15,000 options to buy
@ $67.81, valued at
$1M
Exercised 8,000 options to buy
@ $67.81, valued at
$542.5k
|
|
03/13/2023 |
144
| Form 144 - Report of proposed sale of securities: |
03/10/2023 |
144
| Form 144 - Report of proposed sale of securities: |
03/02/2023 |
4
| BIENAIME JEAN JACQUES (CEO) has filed a Form 4 on BIOMARIN PHARMACEUTICAL INC
Txns:
| Granted 89,700 shares
@ $0 Granted 44,860 shares
@ $0 Granted 32,972 shares
@ $0 |
|
02/14/2023 |
4
| BIENAIME JEAN JACQUES (CEO) has filed a Form 4 on BIOMARIN PHARMACEUTICAL INC
Txns:
| Gifted 200 shares
@ $0 Gifted 100 shares
@ $0 Sold 15,000 shares
@ $110.11, valued at
$1.7M
Exercised 6,000 shares
@ $67.81, valued at
$406.9k
Sold 6,000 shares
@ $109.15, valued at
$654.9k
Exercised 15,000 options to buy
@ $67.81, valued at
$1M
Exercised 6,000 options to buy
@ $67.81, valued at
$406.9k
|
|
02/13/2023 |
5
| Form 5 - Annual statement of changes in beneficial ownership of securities: |
01/18/2023 |
4
| BIENAIME JEAN JACQUES (CEO) has filed a Form 4 on BIOMARIN PHARMACEUTICAL INC
Txns:
| Sold 10,000 shares
@ $112.25, valued at
$1.1M
Sold 10,000 shares
@ $111.55, valued at
$1.1M
Exercised 10,000 options to buy
@ $67.81, valued at
$678.1k
Exercised 10,000 options to buy
@ $67.81, valued at
$678.1k
|
|
12/15/2022 |
4
| BIENAIME JEAN JACQUES (CEO) has filed a Form 4 on BIOMARIN PHARMACEUTICAL INC
Txns:
| Sold 1,000 shares
@ $106.89, valued at
$106.9k
|
|
12/06/2022 |
4
| BIENAIME JEAN JACQUES (CEO) has filed a Form 4 on BIOMARIN PHARMACEUTICAL INC
Txns:
| Small acquisition of 100 shares
@ $86.1178, valued at
$8.6k
Sold 471 shares
@ $103.97, valued at
$49k
Sold 600 shares
@ $103.971, valued at
$62.4k
Sold 260 shares
@ $103.98, valued at
$27k
Sold 100 shares
@ $104, valued at
$10.4k
Sold 69 shares
@ $104.055, valued at
$7.2k
|
|
10/18/2022 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
08/16/2022 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
06/17/2022 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
05/09/2022 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
05/02/2022 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
04/20/2022 |
4
| BIENAIME JEAN JACQUES (CEO) has filed a Form 4 on BIOMARIN PHARMACEUTICAL INC
Txns:
| Sold 20,000 shares
@ $81.91, valued at
$1.6M
Exercised 20,000 options to buy
@ $37.46, valued at
$749.2k
|
|
04/18/2022 |
4
| BIENAIME JEAN JACQUES (CEO) has filed a Form 4 on BIOMARIN PHARMACEUTICAL INC
Txns:
| Sold 10,000 shares
@ $83.66, valued at
$836.6k
Exercised 10,000 options to buy
@ $37.46, valued at
$374.6k
|
|
03/17/2022 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
03/14/2022 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
03/10/2022 |
4
| BIENAIME JEAN JACQUES (CEO) has filed a Form 4 on BIOMARIN PHARMACEUTICAL INC
Txns:
| Granted 34,780 shares
@ $0 |
|
01/14/2022 |
4
| BIENAIME JEAN JACQUES (CEO) has filed a Form 4 on BIOMARIN PHARMACEUTICAL INC
Txns:
| Small acquisition of 100 shares
@ $89.2246, valued at
$8.9k
Sold 5,000 shares
@ $89, valued at
$445k
Sold 5,000 shares
@ $87.86, valued at
$439.3k
Exercised 5,000 options to buy
@ $37.46, valued at
$187.3k
Exercised 5,000 options to buy
@ $37.46, valued at
$187.3k
|
|
12/17/2021 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
12/02/2021 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
|
|
|